Hur Hyuk, Ko Yong Taek, Min Byung Soh, Kim Kyung Sik, Choi Jin Sub, Sohn Seung Kook, Cho Chang Hwan, Ko Heung Kyu, Lee Jong Tai, Kim Nam Kyu
Colorectal Cancer Clinic, Severance Hospital, Yonsei University Health System, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Am J Surg. 2009 Jun;197(6):728-36. doi: 10.1016/j.amjsurg.2008.04.013. Epub 2008 Sep 11.
We compared outcomes in patients with solitary colorectal liver metastases treated by either hepatic resection (HR) or radiofrequency ablation (RFA).
A retrospective analysis from a prospective database was performed on 67 consecutive patients with solitary colorectal liver metastases treated by either HR or RFA.
Forty-two patients underwent HR and 25 patients underwent RFA. The 5-year overall and local recurrence-free survival rates after HR (50.1% and 89.7%, respectively) were higher than after RFA (25.5% and 69.7%, respectively) (P = .0263 and .028, respectively). In small tumors less than 3 cm (n = 38), the 5-year survival rates between HR and RFA were similar, including overall (56.1% vs 55.4%, P = .451) and local recurrence-free (95.7% vs 85.6%, P = .304) survival rates. On multivariate analysis, tumor size, metastases treatment, and primary node status were significant prognostic factors.
HR had better outcomes than RFA for recurrence and survival after treatment of solitary colorectal liver metastases. However, in tumors smaller than 3 cm, RFA can be recommended as an alternative treatment to patients who are not candidates for surgery because the liver metastases is poorly located anatomically, the functional hepatic reserve after a resection would be insufficient, the patient's comorbidity inhibits a major surgery, or extrahepatic metastases are present.
我们比较了接受肝切除(HR)或射频消融(RFA)治疗的孤立性结直肠癌肝转移患者的预后。
对前瞻性数据库进行回顾性分析,纳入67例连续接受HR或RFA治疗的孤立性结直肠癌肝转移患者。
42例患者接受了HR,25例患者接受了RFA。HR术后5年总生存率和局部无复发生存率(分别为50.1%和89.7%)高于RFA术后(分别为25.5%和69.7%)(P分别为0.0263和0.028)。在小于3 cm的小肿瘤患者中(n = 38),HR和RFA的5年生存率相似,包括总生存率(56.1%对55.4%,P = 0.451)和局部无复发生存率(95.7%对85.6%,P = 0.304)。多因素分析显示,肿瘤大小、转移灶治疗方式和原发淋巴结状态是重要的预后因素。
对于孤立性结直肠癌肝转移的治疗,HR在复发和生存方面的预后优于RFA。然而,对于肝转移灶解剖位置不佳、切除术后功能性肝储备不足、患者合并症限制大手术或存在肝外转移而不适合手术的患者,对于小于3 cm的肿瘤,可推荐RFA作为替代治疗方法。